Crinetics Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
Checking your notes…
(in thousands, except per share data)
| Three months ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenue: | ||
| Product revenue, net | $10,306 | $— |
| Collaboration and license revenue | 428 | 361 |
| Total revenue | 10,734 | 361 |
| Operating expenses: | ||
| Cost of product revenue | 200 | — |
| Research and development | 100,081 | 76,240 |
| Selling, general and administrative | 50,831 | 35,526 |
| Total operating expenses | 151,112 | 111,766 |
| Loss from operations | (140,378) | (111,405) |
| Other income (expense): | ||
| Interest income | 12,664 | 14,834 |
| Other expense, net | (131) | (203) |
| Total other income, net | 12,533 | 14,631 |
| Net loss | (127,845) | (96,774) |
| Net loss per share: | ||
| Net loss per share — basic and diluted | $(1.23) | $(1.04) |
| Weighted average shares — basic and diluted | 104,099 | 93,102 |
| Other comprehensive income (loss): | ||
| Unrealized gain (loss) on investment securities | $(3,147) | $1,033 |
| Unrealized gain on foreign currency | 28 | 6 |
| Total other comprehensive income (loss) | (3,119) | 1,039 |
| Comprehensive loss | $(130,964) | $(95,735) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.